<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545554</url>
  </required_header>
  <id_info>
    <org_study_id>20160227</org_study_id>
    <secondary_id>2017-004972-74</secondary_id>
    <nct_id>NCT04545554</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta</brief_title>
  <official_title>An Open-label, Ascending Multiple-dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics (PK) profile&#xD;
      following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with&#xD;
      Osteogenesis Imperfecta (OI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">May 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-observed Concentration (Cmax) of Romosozumab in Serum</measure>
    <time_frame>Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum-observed Concentration (tmax) of Romosozumab in Serum</measure>
    <time_frame>Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Romosozumab in Serum</measure>
    <time_frame>Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) of Romosozumab in Serum</measure>
    <time_frame>Up to Day 169</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experience Treatment-emergent Adverse Events</measure>
    <time_frame>Day 0 (post study drug administration) to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Clinically Significant Change from Baseline in Vital Sign Measurements</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes from Baseline in Electrocardiogram (ECG) Results</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes from Baseline in Physical Examination Results</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes from Baseline in Safety Laboratory Tests</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Antiromosuzomab Antibodies</measure>
    <time_frame>Up to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Bone Turnover Marker: Procollagen Type 1 N-terminal Propeptide (P1NP)</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Bone Turnover Marker: Serum C-telopeptide (CTX)</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Bone Mineral Density (BMD) at the Anteroposterior Lumbar Spine</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Bone Mineral Content (BMC)</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Bone Area</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Bone Mineral Density (BMD) Z-Score at Anteroposterior Lumbar Spine</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Romosozumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Participants will receive 3 doses of romosozumab via a subcutaneous (SC) injection.</description>
    <arm_group_label>Romosozumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>All participants will receive daily supplements of elemental calcium.</description>
    <arm_group_label>Romosozumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>All participants will receive daily supplementation with vitamin D.</description>
    <arm_group_label>Romosozumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory male or female children 5 to 18 years of age upon entry into screening&#xD;
&#xD;
          -  Clinical diagnosis of OI defined as a clinical history consistent with type I-IV OI as&#xD;
             determined by presence of expected phenotype and lack of additional features unrelated&#xD;
             to type I-IV OI&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of an electrophoresis pattern inconsistent with type I to type IV OI&#xD;
&#xD;
          -  History of known mutation in a gene other than collagen type I alpha/collagen type I&#xD;
             alpha 2 (COL1AI/COL1A2) causing OI or other metabolic bone disease&#xD;
&#xD;
          -  History of other bone diseases that affect bone metabolism (eg, osteoporosis&#xD;
             pseudoglioma syndrome, idiopathic juvenile osteoporosis, osteopetrosis,&#xD;
             hypophosphatasia)&#xD;
&#xD;
          -  History of Kawasaki disease, rheumatic myocarditis, ischemic cardiomyopathy, inherited&#xD;
             cardiomyopathies, valvular heart disease, nephrotic syndrome, familial&#xD;
             hypercholesterolemia, stroke, or any thromboembolic disorder&#xD;
&#xD;
          -  Unhealed fracture as defined by orthopedic opinion&#xD;
&#xD;
          -  Symptoms associated with skull abnormalities such as basilar invagination, basilar&#xD;
             impression or Chiari malformation&#xD;
&#xD;
          -  Prior treatment with anti-sclerostin antibody, fluoride or strontium, parathyroid&#xD;
             hormone (PTH) within 12 months prior to screening, denosumab within 12 months or&#xD;
             zoledronic acide with in 6 months prior to first dose&#xD;
&#xD;
          -  Less than 2 evaluable vertebrae by DXA evaluation in the region of interest, L1 L4, as&#xD;
             confirmed by the central imaging laboratory.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Children Hospital Panagioti and Aglaias Kyriakou</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesu</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Cataluña</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Baracaldo</city>
        <state>País Vasco</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gazi Universitesi Tip Fakultesi</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koc Universitesi Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Ilac Gelistirme ve Farmakokinetik Arastirma Uygulama Merkezi (ARGEFAR)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

